[email protected]
Research paper published by the Actinogen team diving into the current literature on 11BHSD1 inhibition. They describe some potential future indications for Xanamem but nothing conclusive - the science is still quite unclear on this one unfortunately.
- Forums
- ASX - By Stock
- ACW
- 11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
6.5¢ |
Change
0.003(4.84%) |
Mkt cap ! $174.3M |
Open | High | Low | Value | Volume |
6.4¢ | 7.1¢ | 5.1¢ | $2.369M | 37.36M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 6.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.5¢ | 625867 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.063 |
4 | 520805 | 0.062 |
5 | 1185000 | 0.060 |
1 | 1000000 | 0.058 |
1 | 1000000 | 0.057 |
Price($) | Vol. | No. |
---|---|---|
0.065 | 625867 | 3 |
0.070 | 221609 | 3 |
0.071 | 456986 | 7 |
0.072 | 1366832 | 4 |
0.073 | 175000 | 2 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online